Tempest Therapeutics, Inc. — Director's Dealing 2018

Dec 12, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Millendo Therapeutics, Inc. (MLND)
CIK: 0001544227
Period of Report: 2018-12-07

Reporting Person: Hedley Mary Lynne (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-12-07	Stock Option (right to buy)	$16.40	A	18600	Acquired	2028-08-23	Common Stock (18600)	Direct

Footnotes

F1: Twenty-five percent (25%) of the shares subject to the option vested on February 24, 2018, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.

F2: Received in connection with the merger of Millendo Therapeutics, Inc. ("Millendo") into the Issuer in exchange for a stock option to acquire 250,000 shares of Millendo common stock for $1.22 per share.